SELLAS Life Sciences (SLS) Retained Earnings (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Retained Earnings for 9 consecutive years, with -$241.4 million as the latest value for Q3 2024.
- On a quarterly basis, Retained Earnings fell 15.44% to -$241.4 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$241.4 million, a 15.44% decrease, with the full-year FY2023 number at -$217.2 million, down 20.76% from a year prior.
- Retained Earnings was -$241.4 million for Q3 2024 at SELLAS Life Sciences, down from -$234.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$105.3 million in Q1 2020 to a low of -$241.4 million in Q3 2024.
- A 5-year average of -$165.9 million and a median of -$163.8 million in 2022 define the central range for Retained Earnings.
- Peak YoY movement for Retained Earnings: dropped 13.84% in 2021, then tumbled 31.11% in 2022.
- SELLAS Life Sciences' Retained Earnings stood at -$117.9 million in 2020, then dropped by 17.56% to -$138.6 million in 2021, then dropped by 29.8% to -$179.9 million in 2022, then dropped by 20.76% to -$217.2 million in 2023, then fell by 11.12% to -$241.4 million in 2024.
- Per Business Quant, the three most recent readings for SLS's Retained Earnings are -$241.4 million (Q3 2024), -$234.3 million (Q2 2024), and -$226.8 million (Q1 2024).